

REMARKS


Claims 1-38 were pending in this application and have been canceled without prejudice or disclaimer. New Claims 39-45 have been added which recite the functional recitation: "wherein said polypeptide is capable of inducing c-fos in endothelial cells," support for which is found in the instant specification, at least in Example 84, (page 214). Example 84 of the present application provides detailed protocols for the endothelial cell c-fos induction assay, including the extensive step-by-step guidance.

In addition, this response is being concurrently filed with a Terminal Disclaimer to overcome any potential obviousness-type double-patenting rejections over the claimed subject matter of co-pending U.S. Patent Application Serial No. 09/904,485. An amendment to correct inventorship under 37 C.F.R. § 1.48(b) is also concurrently filed.

Applicants respectfully request entry of the present amendments and consideration of the documents filed herewith.

The Commissioner is authorized to charge any fees, including any fees for additional extension of time, or credit overpayment to Deposit Account No. 08-1641 (Attorney Docket No. 39780-1618 P2C1-1).

Respectfully submitted,


Daphne Reddy
Reg. No. 53,507

Date: June 28, 2006

HELLER EHRMAN LLP
Customer No. 35489
275 Middlefield Road
Menlo Park, California 94025
Telephone: (650) 324-7000
Facsimile: (650) 324-0638

SV 2217253 v1
6/28/06 11:15 AM (39780.1618)